7:04 AM ET
8-K
Court & Legal Update
Alkermes Court & Legal Update
Alkermes entered into a settlement and license agreement with Teva Pharmaceuticals to resolve a patent infringement lawsuit regarding LYBALVI. Under the agreement, Teva is granted a non-exclusive, royalty-free license to market its generic version of the drug in the U.S. starting in November 2039, or May 2040 if pediatric exclusivity is obtained.
- Counterparty
- Teva Pharmaceuticals, Inc.